Related references
Note: Only part of the references are listed.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
D. Zheng et al.
SCIENTIFIC REPORTS (2016)
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure
Shinichi Sasaki et al.
RESPIRATORY INVESTIGATION (2016)
Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer
Guanshan Zhu et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases
Haihong Yang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Rebiopsy of Non-Small Cell Lung Cancer Patients With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Akito Hata et al.
CANCER (2013)
Cerebrospinal Fluid Concentrations of Gefitinib in Patients With Lung Adenocarcinoma
Jing Zhao et al.
CLINICAL LUNG CANCER (2013)
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung
Youngjoo Lee et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
Rebecca J. Leary et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Frequent Central Nervous System Failure After Clinical Benefit With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Korean Patients With Nonsmall-Cell Lung Cancer
Young Joo Lee et al.
CANCER (2010)
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
A-M. Ruppert et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
Tatsuya Katayama et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib
Sanjay Popat et al.
LUNG CANCER (2007)
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
AMP Omuro et al.
CANCER (2005)
Current management of brain metastases, with a focus on systemic options
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials
HK Jones et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2002)
Share Paper
